Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.
Moujalled DM, Hanna DT, Hediyeh-Zadeh S, Pomilio G, Brown L, Litalien V, Bartolo R, Fleming S, Chanrion M, Banquet S, Maragno AL, Kraus-Berthier L, Schoumacher M, Mullighan CG, Georgiou A, White CA, Lessene G, Huang DCS, Roberts AW, Geneste O, Rasmussen L, Davis MJ, Ekert PG, Wei A, Ng AP, Khaw SL.
Moujalled DM, et al. Among authors: white ca.
Blood Adv. 2020 Jun 23;4(12):2762-2767. doi: 10.1182/bloodadvances.2019001416.
Blood Adv. 2020.
PMID: 32569380
Free PMC article.